These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 23999199)

  • 1. Vorinostat-induced bone loss might be related to drug toxicity.
    Xu S; De Veirman K; Vanderkerken K; Van Riet I
    Bone; 2013 Dec; 57(2):384-5. PubMed ID: 23999199
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to vorinostat induced bone loss in mice.
    McGee-Lawrence ME; Westendorf JJ
    Bone; 2013 Dec; 57(2):531-2. PubMed ID: 23973558
    [No Abstract]   [Full Text] [Related]  

  • 3. Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity.
    Warlick ED; Cao Q; Miller J
    Leukemia; 2013 Aug; 27(8):1789-91. PubMed ID: 23446311
    [No Abstract]   [Full Text] [Related]  

  • 4. Histone deacetylase inhibitors: Are they here to stay?
    Ibrahim RB
    Am J Health Syst Pharm; 2010 May; 67(10):791. PubMed ID: 20479099
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I.
    Fouliard S; Robert R; Jacquet-Bescond A; du Rieu QC; Balasubramanian S; Loury D; Loriot Y; Hollebecque A; Kloos I; Soria JC; Chenel M; Depil S
    Eur J Cancer; 2013 Sep; 49(13):2791-7. PubMed ID: 23790467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
    Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
    Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPARγ forms a bridge between DNA methylation and histone acetylation at the C/EBPα gene promoter to regulate the balance between osteogenesis and adipogenesis of bone marrow stromal cells.
    Zhao QH; Wang SG; Liu SX; Li JP; Zhang YX; Sun ZY; Fan QM; Tian JW
    FEBS J; 2013 Nov; 280(22):5801-14. PubMed ID: 23981481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vorinostat, a histone deacetylase inhibitor, facilitates fear extinction and enhances expression of the hippocampal NR2B-containing NMDA receptor gene.
    Fujita Y; Morinobu S; Takei S; Fuchikami M; Matsumoto T; Yamamoto S; Yamawaki S
    J Psychiatr Res; 2012 May; 46(5):635-43. PubMed ID: 22364833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits.
    Wise LD; Turner KJ; Kerr JS
    Birth Defects Res B Dev Reprod Toxicol; 2007 Feb; 80(1):57-68. PubMed ID: 17294457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies.
    Ossenkoppele GJ; Lowenberg B; Zachee P; Vey N; Breems D; Van de Loosdrecht AA; Davidson AH; Wells G; Needham L; Bawden L; Toal M; Hooftman L; Debnam PM
    Br J Haematol; 2013 Jul; 162(2):191-201. PubMed ID: 23647373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vorinostat (Zolinza) for cutaneous T-Cell lymphoma.
    Med Lett Drugs Ther; 2007 Mar; 49(1256):23-4. PubMed ID: 17351559
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors.
    Kim DR; Park MY; Lim HJ; Park JS; Cho YJ; Lee SW; Yoon HI; Lee JH; Kim YS; Lee CT
    Int J Mol Med; 2012 Feb; 29(2):218-24. PubMed ID: 22075951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors.
    Cho HH; Park HT; Kim YJ; Bae YC; Suh KT; Jung JS
    J Cell Biochem; 2005 Oct; 96(3):533-42. PubMed ID: 16088945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
    Prebet T; Vey N
    Expert Opin Investig Drugs; 2011 Feb; 20(2):287-95. PubMed ID: 21192773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of female and male fertility in Sprague-Dawley rats administered vorinostat, a histone deacetylase inhibitor.
    Wise LD; Spence S; Saldutti LP; Kerr JS
    Birth Defects Res B Dev Reprod Toxicol; 2008 Feb; 83(1):19-26. PubMed ID: 18092367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
    Modesitt SC; Parsons SJ
    Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.
    Marks PA; Breslow R
    Nat Biotechnol; 2007 Jan; 25(1):84-90. PubMed ID: 17211407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
    Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB
    J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the histone deacetylase inhibitor, trichostatin A, in a chronic allergic airways disease model in mice.
    Royce SG; Dang W; Yuan G; Tran J; El-Osta A; Karagiannis TC; Tang ML
    Arch Immunol Ther Exp (Warsz); 2012 Aug; 60(4):295-306. PubMed ID: 22684086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.